Literature DB >> 22687519

Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.

Kamilia Abdelraouf1, Kirk H Braggs, Taijun Yin, Luan D Truong, Ming Hu, Vincent H Tam.   

Abstract

The increasing prevalence of multidrug-resistant Gram-negative infections has led to renewed interest in the use of systemic polymyxin B. However, the nephrotoxic properties of polymyxin B are still poorly understood. The objective of this study was to characterize nephrotoxicity associated with polymyxin B, with an emphasis on examining the impact of dosing frequencies on the onset of nephrotoxicity. Sprague-Dawley rats were divided into two groups and administered the same total daily dose of polymyxin B subcutaneously but with different dosing frequencies (either 20 mg/kg of body weight every 24 h [q24h] or 5 mg/kg q6h). Drug concentrations in renal tissue were compared between the two groups at 24 h. Kidney tissues were harvested at 48 h and compared histologically. Serum creatinine was measured daily for up to 10 days, and nephrotoxicity was defined as a significant elevation in serum creatinine (≥2× baseline). Kaplan-Meier analysis was used to compare the onset of nephrotoxicity. Polymyxin B-induced nephrotoxicity manifested as elevation in serum creatinine and acute tubular necrosis. Extensive injury of the proximal tubules was observed. The lesions were more severe and higher drug concentrations were achieved in the kidneys of the q6h dosing group. The q24h dosing group experienced a more gradual onset of nephrotoxicity, which could be attributed to the lower kidney tissue drug concentrations (48.5 ± 17.4 μg/g versus 92.1 ± 18.1 μg/g of polymyxin B1, P = 0.04). Preferential accumulation of polymyxin B in the kidneys suggests that uptake to renal cells is a nonpassive process and q24h dosing was less nephrotoxic than q6h dosing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687519      PMCID: PMC3421883          DOI: 10.1128/AAC.00280-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  THE THERAPEUTIC SUCCESS AND NEPHROTOXICITY OF COLISTIN IN ACUTE AND CHRONIC NEPHROPATHIES WITH IMPAIRED RENAL FUNCTION.

Authors:  L G TALLGREN; K LIEWENDAHL; B KUHLBAECK
Journal:  Acta Med Scand       Date:  1965-06

2.  Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Giao Vo; Samer Kabbara; Andrea L Kwa; Nathan P Wiederhold; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections.

Authors:  M E Falagas; P I Rafailidis; S K Kasiakou; P Hatzopoulou; A Michalopoulos
Journal:  Clin Microbiol Infect       Date:  2006-12       Impact factor: 8.067

4.  Fixatives and methods of fixation in selected tissues of the laboratory rat.

Authors:  W D Johnson; C M Lang; M T Johnson
Journal:  Clin Toxicol       Date:  1978       Impact factor: 4.467

5.  Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.

Authors:  David Landman; Simona Bratu; Maqsood Alam; John Quale
Journal:  J Antimicrob Chemother       Date:  2005-05-09       Impact factor: 5.790

6.  High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea.

Authors:  Kwan Soo Ko; Ji Yoeun Suh; Ki Tae Kwon; Sook-In Jung; Kyong-Hwa Park; Cheol In Kang; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song
Journal:  J Antimicrob Chemother       Date:  2007-08-29       Impact factor: 5.790

Review 7.  Back to the future: using aminoglycosides again and how to dose them optimally.

Authors:  George L Drusano; Paul G Ambrose; Sujata M Bhavnani; Joseph S Bertino; Ann N Nafziger; Arnold Louie
Journal:  Clin Infect Dis       Date:  2007-08-08       Impact factor: 9.079

8.  Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs.

Authors:  S K Moestrup; S Cui; H Vorum; C Bregengård; S E Bjørn; K Norris; J Gliemann; E I Christensen
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

9.  Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.

Authors:  Thomas P Lodise; Ben Lomaestro; Jeffrey Graves; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

Review 10.  Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria.

Authors:  Louis B Rice
Journal:  Cleve Clin J Med       Date:  2007-08       Impact factor: 2.321

View more
  42 in total

1.  Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes.

Authors:  Bo Yun; Mohammad A K Azad; Cameron J Nowell; Roger L Nation; Philip E Thompson; Kade D Roberts; Tony Velkov; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

Review 2.  Mechanisms of antimicrobial-induced nephrotoxicity in children.

Authors:  Kevin J Downes; Molly Hayes; Julie C Fitzgerald; Gwendolyn M Pais; Jiajun Liu; Nicole R Zane; Stuart L Goldstein; Marc H Scheetz; Athena F Zuppa
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

3.  Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity.

Authors:  Elijah J Weber; Kevin A Lidberg; Lu Wang; Theo K Bammler; James W MacDonald; Mavis J Li; Michelle Redhair; William M Atkins; Cecilia Tran; Kelly M Hines; Josi Herron; Libin Xu; Maria Beatriz Monteiro; Susanne Ramm; Vishal Vaidya; Martti Vaara; Timo Vaara; Jonathan Himmelfarb; Edward J Kelly
Journal:  JCI Insight       Date:  2018-12-20

4.  Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational In Vivo Rat Model.

Authors:  Jiajun Liu; Gwendolyn M Pais; Sean N Avedissian; Annette Gilchrist; Andrew Lee; Nathaniel J Rhodes; Alan R Hauser; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

5.  In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.

Authors:  Kady Phe; Yuman Lee; Patrick M McDaneld; Nishant Prasad; Taijun Yin; Deborah A Figueroa; William L Musick; Jessica M Cottreau; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

6.  Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells.

Authors:  Mohammad A K Azad; Jesmin Akter; Kelly L Rogers; Roger L Nation; Tony Velkov; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

7.  Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.

Authors:  Adeola Okoduwa; Nabeela Ahmed; Yi Guo; Marco R Scipione; John Papadopoulos; Daniel P Eiras; Yanina Dubrovskaya
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

8.  Evaluation of Risk Factors for Intravenous Colistin Use-related Nephrotoxicity.

Authors:  Iftihar Koksal; Selcuk Kaya; Eda Gencalioglu; Gurdal Yilmaz
Journal:  Oman Med J       Date:  2016-07

9.  Uptake of polymyxin B into renal cells.

Authors:  Kamilia Abdelraouf; Kai-Tai Chang; Taijun Yin; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

10.  Pharmacokinetics and renal disposition of polymyxin B in an animal model.

Authors:  Kamilia Abdelraouf; Jie He; Kimberly R Ledesma; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.